

Special Issue

Biomarkers and Personalized Therapy in Solid Tumors

Message from the Guest Editor

Personalized medicine uses a cancer patient's genetic profile to guide treatment decisions to maximize individual therapeutic benefits. These advancements in molecular genomic profiling provide insight into the molecular heterogeneity of different malignancies, predict clinical outcomes, help develop new therapeutic rationale for cancer treatments, and aid the discovery of new therapeutic options for patients. In this era of personalized medicine, a wide spectrum of molecular techniques and methodologies are being developed to identify the genomic diversity of tumors, including but not limited to protein expression (via IHC) in the tissue and the proteomic analysis of the serum, plasma, peripheral blood, urine, saliva, and other body secretions to generate proteomic fingerprint information to predict outcomes in many malignancies. This Special Issue presents cutting-edge research and clinical advancements in biomarkers in solid tumors. Original papers are especially encouraged; however, high-level systematic reviews or meta-analyses will also be considered for publication.

Guest Editor

Dr. Manik A. Amin

Section of Hematology/Oncology, Norris Cotton Cancer Center,
Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

Deadline for manuscript submissions

closed (25 September 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/175694

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).